Ipamorelin: Selective, but Thinly Studied in Humans

The short version

Ipamorelin is a small, five-amino-acid peptide designed to trigger a pulse of growth hormone release from the pituitary gland. Its defining feature, shown in its founding animal research, is selectivity: unlike older compounds in its family, it does this without meaningfully raising cortisol or prolactin, even at high doses [and see safety notes below]. That selectivity is the main reason it built a following in research communities.

The honest gap is human data. Ipamorelin has exactly one published Phase 2 randomized controlled trial in people — and it missed its primary endpoint ^[10]. Almost everything else known about it comes from rodent, ferret and cell studies, or from one small pharmacokinetic study in eight healthy volunteers ^[11]. It has never been approved as a drug anywhere, and this page treats every claim about it in proportion to how thin that record actually is.

What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — alpha-aminoisobutyric acid at the first position, plus D-2-naphthylalanine and D-phenylalanine, unusual amino-acid forms that make the molecule resistant to being broken down by normal digestive and blood enzymes. It was derived from an earlier peptide, GHRP-1, by removing a central two-amino-acid segment. Pharmacologically it is classed as a selective agonist of the ghrelin receptor, formally called the growth hormone secretagogue receptor (GHS-R1a).

It has no FDA approval for any indication and was investigated once, for postoperative bowel recovery, in a trial that did not demonstrate a benefit over placebo ^[10]. In 2024 the FDA removed ipamorelin acetate from the interim list of substances a compounding pharmacy may legally use, restricting one route by which it had been available.

How it works

Ipamorelin activates the GHS-R1a receptor on pituitary somatotroph cells, the cells responsible for producing growth hormone, triggering a discrete pulse of GH release. Its founding pharmacology showed this happens through a mechanism separate from, and complementary to, growth-hormone-releasing hormone (GHRH) — the basis for the popular research-community practice of pairing it with a GHRH analogue such as CJC-1295, though no trial of that specific combination exists in this dataset.

What sets ipamorelin apart from earlier secretagogues like GHRP-6 is that it does not meaningfully raise ACTH, cortisol or prolactin even at doses far above the amount needed to trigger GH release — a selectivity profile established in animal studies. Because the GHS-R1a receptor it targets is the ghrelin receptor, it also carries ghrelin's other biology: effects on gut motility, and — shown directly in isolated pancreatic tissue — a mechanism for stimulating insulin release that is independent of growth hormone altogether.

What the research shows

The defining human study is a Phase 2 randomized, placebo-controlled trial (NCT00672074) in 114 adults recovering from bowel resection surgery, given ipamorelin intravenously twice daily for up to seven days. It missed its primary endpoint: median time to the first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p=0.15). Adverse events occurred in a similar share of both groups — 87.5% on ipamorelin versus 94.8% on placebo — with no ipamorelin-specific safety signal detected in that short perioperative window ^[10].

A pharmacokinetic study in eight healthy male volunteers per dose, using five short intravenous infusions ranging from about 4 to 140 nanomoles per kilogram, found dose-proportional kinetics: a terminal half-life of roughly two hours, and a single discrete growth-hormone pulse peaking about 40 minutes after dosing ^[11]. This remains one of the only published human ipamorelin datasets of any kind.

The most recent published study, from 2024, tested ipamorelin in ferrets to see whether it could counter chemotherapy-related weight loss. It reduced cisplatin-induced body-weight loss by roughly 24% during the later, delayed phase of the model, but had no measurable anti-emetic (anti-nausea) effect — a contrast with a related compound, anamorelin, which did reduce nausea in the same model ^[8]. In rats, subcutaneous ipamorelin at three dose levels dose-dependently increased longitudinal bone growth rate, from 42 micrometers per day at baseline to as much as 52 micrometers per day at the highest dose, without a measurable change in total circulating IGF-1 ^[12] — suggesting at least part of that skeletal effect happens locally rather than through the standard growth-hormone-to-IGF-1 pathway.

Reported effects, cautions & safety

Community accounts of using ipamorelin, typically alongside a GHRH analogue, are anecdotal, not clinical evidence, and are drawn here from peptide-user forums, blogs and wellness-clinic write-ups rather than from controlled research.

Commonly reported (anecdotal, not clinical evidence): deeper, more restorative sleep is the effect mentioned most often, usually within one to two weeks of a pre-bed protocol, sometimes accompanied by unusually vivid dreams in the early weeks. Faster recovery between training sessions and reduced post-exercise soreness are also frequently described, along with a gradual, subtle shift toward a leaner appearance over several months — though users themselves note this is hard to separate from concurrent diet and training changes.

Commonly reported adverse experiences (anecdotal, not clinical evidence): a warm facial flush shortly after injection, often compared to a niacin flush, is widely noted and lasts up to about an hour. Mild water retention or puffiness, tingling in the hands and feet, increased hunger in the hours after dosing, and minor injection-site irritation are also frequently mentioned. Some users report that the perceived effect fades after several months of continuous use, which lines up with the on/off cycling practices commonly discussed in these communities.

Cited cautions from the literature:

• Growth-hormone-axis stimulation carries a mechanistic, class-level cancer caution. Growth hormone raises hepatic IGF-1, a well-characterized growth signal for cells generally; no ipamorelin-specific tumor-promotion trial exists in any species, so this remains a theoretical, mechanism-based concern rather than an observed event ^[12].
• A related receptor-class compound showed heart-tissue damage in a 28-day rat study. A structurally different GHS-R1a agonist produced dose-dependent myocardial degeneration detectable on biopsy, with no equivalent long-duration cardiovascular study ever run on ipamorelin itself — a class-level signal, not an ipamorelin-specific finding ^[9].
• No long-term human safety data exist. The only controlled human dataset is the single short Phase 2 trial ^[10] and the acute single-dose pharmacokinetic study ^[11]; the subcutaneous self-injection route common in research use has no published human safety characterization at all.
• Ipamorelin's defining selectivity — low cortisol and prolactin impact — is itself evidence from animal, not human, pharmacology ^[11], a relative advantage over older secretagogues rather than proof of an absence of other effects.

Where it fits in lab-grade standards

Ipamorelin is the sharpest illustration on this hub of why a purity certificate cannot substitute for clinical evidence. Its research-grade material is manufactured for laboratory use by unregulated suppliers, with no pharmaceutical quality-assurance process behind it, and the only investigational-grade batch that has ever been through controlled human testing was made specifically for the 2014 trial ^[10] — not the product circulating in research-chemical markets today. A batch's measured purity on the day it was tested says nothing about whether the underlying compound has been shown to do what marketing describes. Reading the actual trial data, rather than a certificate, is the more reliable signal here. See how ipamorelin's evidence base stacks up against GHK-Cu and tesamorelin on the comparison page.